Wednesday, December 16, 2015

Elani Linos


Dermatologist and Public Health Leader Dr. Eleni Linos Comes to Visit the Maverakis Lab.

We had a fun two days with Eleni Linos, MD, DrPH.  Dr. Linos is a dually trained in public health and dermatology.  She is a leader in the field of skin cancer research and prevention. During her stay she gave an amazing grand rounds presentation.

Altered Glycans and Autoimmunity



 Altered Glycans and Autoimmunity



LINK TO ARTICLE

Howard Chang, a columnist for everyday Health, was nice enough to write an article about our research on how glycans (oligosaccharides) are linked to autoimmunity.  Please take a look at his very nice piece.

Thursday, September 17, 2015

Thuy Phung, MD

Dermatopathologist, physician-scientist and global health leader Thuy Phung comes to visit the Maverakis Lab

We had a fun and enlightening 3 days with her.   Dr. Phung is one of the founders of an award-winning dermatology clinic in Vietnam that specializes in treating children with vascular malformations. She is also faculty at the Baylor College of Medicine.  Her laboratory has made seminal discoveries on how abnormal blood vessels grow.  She came to visit the Maverakis Lab and also give Grand Rounds at UC Davis.




Saturday, August 29, 2015

Dr. Maverakis on CBS News

Dr. Maverakis meets with CBS Channel 13 to talk about Drinkable sunscreens. 


Carotenoids and other components of drinkable sunscreens can provide a minimal amount of sun protection but should not be considered a replacement for your topical sunscreen.



Saturday, August 22, 2015

Altered Glycan Theory of Autoimmunity

The Altered Glycan Theory of Autoimmunity


In this article we put forth the Glycan Theory of Autoimmunity, which states that each autoimmune disease will have a unique glycan signature.  We also review how glycans are important components of the immune system and how they bestow effector function to a variety of molecules.

 2015 Feb;57:1-13. doi: 10.1016/j.jaut.2014.12.002. Epub 2015 Jan 9.

Below is a link to the article.  Please take a look!



Tuesday, August 18, 2015

Dual mTOR inhibition and Scleroderma

Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma




In this article we demonstrated that dual mTOR inhibition can prevent TGF-beta-inudced fibrosis.  These results have implications for scleroderma. 

 2015 Jul 2. doi: 10.1038/jid.2015.252. [Epub ahead of print]



Thursday, August 13, 2015

Intralesional therapy for melanoma

100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series

In this article we report the results of 11 melanoma patients treated with intralesional IL-2 with imiquimod for in-transit mets.The combination therapy worked very well.  Link to Article